NAS:OKUR (USA)
Â
Class A Shares
$
4.12
-0.14 (-3.29%)
10:08 PM EST
Business Description
OnKure Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US68277Q1058
Share Class Description:
OKUR: Class A SharesTotal Employee Number:
45Description
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 469.7 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -25.4 | |||||
3-Year EPS without NRI Growth Rate | -25.8 | |||||
3-Year FCF Growth Rate | -22.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.33 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.86 | |||||
9-Day RSI | 36.76 | |||||
14-Day RSI | 42.99 | |||||
3-1 Month Momentum % | -5.62 | |||||
6-1 Month Momentum % | 33.76 | |||||
12-1 Month Momentum % | 68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.78 | |||||
Quick Ratio | 13.78 | |||||
Cash Ratio | 13.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -82.67 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -61.74 | |||||
ROA % | -56.53 | |||||
ROIC % | -1545.07 | |||||
3-Year ROIIC % | -6179.52 | |||||
ROC (Joel Greenblatt) % | -4916.86 | |||||
ROCE % | -62.09 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.92 | |||||
Price-to-Tangible-Book | 0.92 | |||||
EV-to-EBIT | 0.39 | |||||
EV-to-EBITDA | 0.39 | |||||
EV-to-Forward-Revenue | 130.48 | |||||
EV-to-FCF | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 0.92 | |||||
| Price-to-Net-Cash | 0.95 | |||||
Earnings Yield (Greenblatt) % | 256.41 | |||||
FCF Yield % | -30.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OKUR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OnKure Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.33 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 72.29 | ||
| 14-Day RSI | 42.99 | ||
| 14-Day ATR ($) | 0.349153 | ||
| 20-Day SMA ($) | 4.377 | ||
| 12-1 Month Momentum % | 68 | ||
| 52-Week Range ($) | 1.91 - 5.38 | ||
| Shares Outstanding (Mil) | 40.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OnKure Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OnKure Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 29 days | ||
| General meeting for 2026 | 2026-06-03 09:00 | 4.22 (+1.20%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 4.60 (-5.74%) | ||
| Annual report for 2025 | 2026-03-12 | 3.53 (-1.94%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 3.53 (-1.94%) | ||
| Evercore Healthcare Conference | 2025-12-03 12:30 | 2.62 (-7.42%) | ||
| Stifel Healthcare Conference | 2025-11-12 16:00 | 3.17 (+4.28%) | ||
| Guggenheim Healthcare Innovation Conference | 2025-11-10 16:00 | 2.94 (-4.55%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 3.00 (-3.54%) |
Show
Entries
OnKure Therapeutics Inc Frequently Asked Questions
What is OnKure Therapeutics Inc(OKUR)'s stock price today?
The current price of OKUR is $4.12. The 52 week high of OKUR is $5.38 and 52 week low is $1.91.
When is next earnings date of OnKure Therapeutics Inc(OKUR)?
The next earnings date of OnKure Therapeutics Inc(OKUR) is 2026-08-12 Est..
Does OnKure Therapeutics Inc(OKUR) pay dividends? If so, how much?
OnKure Therapeutics Inc(OKUR) does not pay dividend.
Guru Commentaries on NAS:OKUR
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on OnKure Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers